Skip to main content
ACET
NASDAQ Life Sciences

Adicet Bio Reports Reduced Q1 Net Loss, Extends Cash Runway into 2H 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.17
Mkt Cap
$77.443M
52W Low
$6.01
52W High
$17.438
52W Position info
36% above low
Off High info
53% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ACET sits 36% above its 52-week low of $6.01 on light trading volume (0.3× avg).

Summary

Adicet Bio reported a reduced net loss and significantly lower operating expenses for Q1 2026, extending its cash runway into the second half of 2027, a key positive for the clinical-stage biotech.


Key Events · Earnings and Guidance · ACET

  • Reduced Net Loss in Q1 2026

    The company reported a net loss of $20.2 million for Q1 2026, a 28% improvement compared to a net loss of $28.2 million in Q1 2025.

  • Significant Reduction in Operating Expenses

    Total operating expenses decreased by 28% to $21.57 million in Q1 2026 from $29.885 million in Q1 2025, driven by a 23% reduction in R&D and a 42% reduction in G&A expenses.

  • Extended Cash Runway

    Adicet Bio expects its $137.6 million in cash, cash equivalents, and short-term investments (as of March 31, 2026) to fund operations into the second half of 2027.

  • RA Capital Share Exchange

    In April 2026, RA Capital exchanged 250,000 common shares for pre-funded warrants to acquire 250,000 shares. The common shares were retired, reducing the number of outstanding common shares.


Analysis · ACET · Life Sciences

Adicet Bio's Q1 2026 financial results show significant operational improvements, with a 28% reduction in net loss and a 28% decrease in total operating expenses, driven by cuts in both R&D and G&A. Critically, the company has extended its cash runway into the second half of 2027, providing a longer operational timeline for its clinical programs. This positive financial trajectory follows a period of significant dilution and a reverse stock split in late 2025, suggesting improved financial management and a more stable outlook for a clinical-stage biotech.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACET was trading at $8.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4M. The 52-week trading range was $6.01 to $17.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACET - Latest Insights

ACET
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.95
Real-time Price: $2.20 info
Change: -$0.7482 (-25%) info
Market Cap: $20.034M info
ACET
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.95
Real-time Price: $2.20 info
Change: -$0.7482 (-25%) info
Market Cap: $20.034M info
ACET
Sep 28, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.96
Real-time Price: $2.20 info
Change: -$6.76 (-75%) info
Market Cap: $20.034M info
ACET
Sep 28, 2026, 6:45 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $9.99
Real-time Price: $2.20 info
Change: -$7.79 (-78%) info
Market Cap: $20.034M info
ACET
Sep 01, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.72
Real-time Price: $2.20 info
Change: -$6.52 (-75%) info
Market Cap: $20.034M info